When was AltheaDx founded?

AltheaDx was founded in 2009 and raised its 1st funding round within a year of its incorporation.

Where is AltheaDx located?

AltheaDx is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does AltheaDx have?

As of Dec 31, 2022, AltheaDx has 12 employees, reflecting a 200% year-over-year growth in headcount.

Is AltheaDx a funded company?

AltheaDx is a funded company, having raised a total of $94.7M across 14 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 19, 2009.

When was the latest funding round of AltheaDx?

AltheaDx's latest funding was a $***** Series D round on Dec 04, 2020, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.17B in funding in 2026 to date.

Where does AltheaDx rank among its competitors?

AltheaDx ranks 49th amongst 357 active competitors, of which 121 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Adela, which secured $5M in Apr, 2026.

Who are the top competitors of AltheaDx?

AltheaDx's top competitors include MedGenome, Caris Life Sciences and Geneoscopy. Among them, Adela secured the most recent funding round in April, 2026.

AltheaDx - 2026 Company Profile, Team, Funding & Competitors

Q: Is AltheaDx an acquired company?

AltheaDx got acquired by Castle Biosciences on Apr 04, 2022.

Company Details

AltheaDx, Inc. provides molecular diagnostics and PCR-based services. It offers molecular biomarker discovery, assay development, assay validation, and prospective/retrospective clinical trial testing services. The company also provides gene expression and genotyping analysis for pre-clinical and clinical applications. In addition, it offers discovery services, such as microarray analysis, real-time PCR, next-gen sequencing, quantitative PCR, mutation scanning, data analysis, race assay, and therapeutic siRNA; and diagnostic development services. Further, the company provides clinical trial services, such as enhanced clinical trial, predictive drug response, patient stratification and monitoring.

Website: altheadx.com
Social
Registered Address: San Diego, California

Key Metrics

Founded Year

2009

Location

San Diego, United States

Stage

Acquired

Total Funding

$94.7M in 14 rounds

Latest Funding Round

Series D, Dec 04, 2020, $*****

Investors

Telegraph Hill Partners & 4 more

Ranked

49^th among 357 active competitors

Employee Count

12 as on Dec 31, 2022

Similar Companies

MedGenome & 504 more

Exit Details

Acquired by Castle Biosciences (Apr 04, 2022)

View AltheaDx's full profile

AltheaDx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ALTHEADX, INC. CIN: 262018451 , United States, Active		-	12 (As on Dec 31, 2020)	-

AltheaDx got acquired by Castle Biosciences on Apr 04, 2022 at an acquisition amount of $*****.

Click here to take a look at AltheaDx's acquisition in detail

AltheaDx has raised a total funding of $94.7M over 14 rounds. Its first funding round was on Aug 19, 2009. AltheaDx has 5 institutional investors.

Here is the list of recent funding rounds of AltheaDx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 04, 2020	4052163	Series D	6044641	5453972	4136380	3049706
Oct 11, 2019	3608945	Series D	4266701	9811770	1167237	8439173
Jan 15, 2019	8629800	Series D	5978899	9356192	6918868	8428369

Access funding benchmarks and valuations. Sign up today!

View details of AltheaDx's funding rounds and investors

The founders of AltheaDx is Francois Ferre.

Here are the details of AltheaDx's key team members:

Francois Ferre: Co-Founder of AltheaDx.
Greg Hamilton: CEO of AltheaDx.

View details of AltheaDx's Founder profiles and Board Members

AltheaDx's employee count trend

AltheaDx has 12 employees as of Dec 22. The total employee count is 200.0% more than what it was in Dec 21. Here is AltheaDx's employee count trend over the years:

Uncover AltheaDx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AltheaDx include MedGenome, Caris Life Sciences and Geneoscopy. Here is the list of Top 10 competitors of AltheaDx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	71/100
2nd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	70/100
3rd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
4th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Novartis & 10 others	66/100
5th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, Khosla Ventures & 16 others	63/100
6th	Precipio Diagnostics 1997, New Haven (United States), Public	Provider of cancer diagnostics and second opinion tools	$800K	Enhanced Capital, Connecticut Innovations ... & 3 others	63/100
7th	Adela 2021, San Francisco (United States), Series A	Developer of a platform for detection of cancer	$139M	LabCorp, Deerfield Mg & 5 others	62/100
8th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Foresite Capital & 11 others	62/100
9th	Ambrx 2003, San Diego (United States), Acquired	Developer of Antibody drug conjugates to treat cancers, metabolic disorders and cardiovascular disorders	$346M	Glynn Capital, Fidelity Investments & 24 others	61/100
10th	Exicure 2009, Skokie (United States), Public	developer of gene silencing & immunomodulatory drugs using spherical nucleic acid (SNA) technology	$72.3M	Abbott Biotech Ventures, Luye Pharma & 18 others	61/100
49th	AltheaDx 2009, San Diego (United States), Acquired	Molecular biomarker discovery, assay development and validation, clinical trial testing and companion diagnostics development services.	$94.7M	ALMA Life Sciences, 6 Dimensions Capital & 3 others	51/100